Investigational drug · Phase 2
NPT 2042
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epilepsy, Generalized, Epilepsy, Absence.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "NPT 2042"
First trial start
2025
Mar 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NPT 2042", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epilepsy, Generalized
- Epilepsy, Absence
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NPT 2042" as an intervention, largest first.
NeuroPro Therapeutics, Inc.Industry
NCT05503511 · 50 participants · Start Oct 20, 2022 · Primary completion Mar 17, 2023
Drug: NPT 2042 (bumetanide analog) or Matching Placebo · For: Epilepsy; Alzheimer Disease; Epilepsy Intractable
Sites: Lincoln, Nebraska
NeuroPro Therapeutics, Inc.Industry
NCT06769659 · 14 participants · Start Mar 11, 2025 · Primary completion Aug 17, 2026
Drug: NPT 2042 · For: Epilepsy, Generalized; Epilepsy, Absence
Sites: Little Rock, Arkansas
NeuroPro Therapeutics, Inc.Industry
NCT07222878 · 8 participants · Start Sep 29, 2025 · Primary completion Nov 4, 2025
Drug: NPT 2042 (Reference formula/Formulation 1); NPT 2042 (Test formula/Formulation 2) and 1 more · For: Epilepsy; Alzheimer Disease; Epilepsy Intractable
Sites: Lincoln, Nebraska
NeuroPro Therapeutics, Inc.Industry
NCT06525649 · 5 participants · Start Aug 21, 2024 · Primary completion Jun 26, 2025
Drug: NPT 2042 · For: Photosensitive Epilepsy; Epilepsy
Sites: Little Rock, Arkansas; Boise, Idaho
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.